Evidence map›Paper›PMID 42483057›Full record

ArticleFrontiers in public health2026

Evaluation of the GenoScreen Deeplex Myc-TB workflow for drug-resistant tuberculosis testing in South Africa.

Jennifer Williams, Janré Steyn, Melanie Grobbelaar, Fahd Naufal, Yonas Ghebrekristos, Nabila Ismail, Jason Limberis, Christoffel Opperman, Sarishna Singh, Rouxjeane Venter and 6 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jennifer Williams *Division of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Janré Steyn *Division of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Melanie GrobbelaarDivision of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Fahd NaufalDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, United States.
Yonas GhebrekristosDivision of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Nabila IsmailDivision of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Jason LimberisDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, United States.
Christoffel OppermanDivision of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Sarishna SinghDivision of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Rouxjeane VenterDivision of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Brendon C MannDivision of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Felicia B HunterDivision of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Alina NalyvaykoDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, United States.
Grant TheronDivision of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Robin M Warren *Division of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
John Z Metcalfe *Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, United States.

Funding

Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosisR01AI153213 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David M Engelthaler, John Zapata Metcalfe · 2021 to 2026
$3.7M
NIAID NIH HHS R01 AI153213
6 · The paper itself

Abstract

Tuberculosis (TB) remains a leading cause of death globally, particularly in low- and middle-income countries, where healthcare systems are under-resourced and the burden of drug-resistant disease is highest. We assessed the feasibility of future integration of the GenoScreen Deeplex Myc-TB assay - a targeted next-generation sequencing (tNGS) assay for

Indexed as

High-Throughput Nucleotide SequencingMycobacterium tuberculosisTuberculosis, Multidrug-ResistantWorkflowHumansSouth AfricaDeeplex Myc-TBdrug-resistant tuberculosistargeted next-generation sequencingtuberculosisworkflow optimisation

Identifiers

PMID42483057
PMCPMC13385177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.